Phase 3 Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 50 and 89 years old
• People whose vision in the study eye falls within a specific range on a standard eye chart test (confirm with trial site for exact letter score details)
• People who have been diagnosed with a specific type of age-related macular degeneration (AMD) affecting the central part of the retina, and who have already received anti-VEGF injections (a common eye treatment for AMD) for it
• People whose study eye has already had cataract surgery at least 12 weeks before joining the trial, with the natural lens replaced by an artificial one
• People who have shown a meaningful improvement in response to their previous anti-VEGF eye injections
• People who are willing and able to sign a written consent form agreeing to take part

For the two-eye treatment part of the trial (if applicable):

• People whose vision in both eyes falls within a specific range on a standard eye chart test (confirm with trial site)
• People who have the same AMD-related condition in both eyes
• People who have had cataract surgery with an artificial lens in both eyes, at least 12 weeks before joining
• People who still have active disease in the relevant eye at the time of joining

Who may not be able to join:

• People whose eye condition causing abnormal blood vessel growth or retinal swelling is due to something other than AMD
• People who have significant scarring or tissue loss at the central part of the retina in the study eye
• People whose study eye has another condition that, in the doctor's opinion, would prevent vision from improving
• People who have severe glaucoma, or a history of a certain type of secondary glaucoma, in the study eye
• People who have had a heart attack, stroke, or mini-stroke within the past 6 months
• People who have had eye surgery in the study eye within 12 weeks before being enrolled in the trial
• People who have received certain types of injections into the study eye (such as steroid injections or experimental treatments) — other than standard AMD injections — within a specific timeframe before the trial (confirm with trial site for exact timing details)
• People who have previously received gene therapy treatment of any kind

For the two-eye treatment part of the trial (if applicable), most of the above exclusions apply to both eyes or the second eye, depending on participation type (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.